Abstract: Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.

Abstract: The present invention is directed to devices having a substance receiving portion; a membrane; and at least one blocking member configured for taking one position and another position to allow fluid communication when a vacuum force is applied to the bottom of the substance receiving portion for the purpose of an in-situ preparation of a sample to detect the presence of, and/or quantify, clottable fibrinogen. The present invention is also directed to corresponding methods, processes and systems.

Abstract: The present invention is directed to devices having a substance receiving portion; a membrane; and at least one blocking member configured for taking one position and another position to allow fluid communication when a vacuum force is applied to the bottom of the substance receiving portion for the purpose of an in-situ preparation of a sample to detect the presence of, and/or quantify, clottable fibrinogen. The present invention is also directed to corresponding methods, processes and systems.

Abstract: Provided herein is a plasma-supplemented fibrinogen and/or fibrin formulation, method for the preparation and use thereof.

Abstract: Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.

Abstract: The present invention is directed to devices having a substance receiving portion; a membrane; and at least one blocking member configured for taking one position and another position to allow fluid communication when a vacuum force is applied to the bottom of the substance receiving portion for the purpose of an in-situ preparation of a sample to detect the presence of, and/or quantify, clottable fibrinogen. The present invention is also directed to corresponding methods, processes and systems.

Abstract: Provided is a method, device and system for an in-situ preparation of a sample, for example, for use in detecting the presence of, and/or quantifying, clottable fibrinogen in such a sample.

Abstract: The present invention, in some embodiments thereof, relates to material science in general, and, more particularly, to sequence variants of Stable Protein 1 (SP1), to uses thereof, for binding of carbon nanotubes, production of composite polymers and polymer materials, such as fabrics, based on SP1-polypeptide-carbon nanotube-complexes, and the use thereof for enhancing conductivity in tire.

Abstract: Provided is a method, device and system for an in-situ preparation of a sample, for example, for use in detecting the presence of, and/or quantifying, clottable fibrinogen in such a sample.

Abstract: Provided herein is a plasma-supplemented fibrinogen and/or fibrin formulation, method for the preparation and use thereof.

Abstract: The present invention, in some embodiments thereof, relates to material science in general, and, more particularly, to sequence variants of Stable Protein 1 (SP1), to uses thereof, for binding of carbon nanotubes, production of composite polymers and polymer materials, such as fabrics, based on SP1-polypeptide-carbon nanotube-complexes, and the use thereof for enhancing conductivity in tire.

Abstract: The present invention, in some embodiments thereof, relates to material science in general, and, more particularly, to sequence variants of Stable Protein 1 (SP1), to uses thereof, for binding of carbon nanotubes, production of composite polymers and polymer materials, such as fabrics, based on SP1-polypeptide-carbon nanotube-complexes, and the use thereof for enhancing conductivity in tire.

Abstract: The present invention, in some embodiments thereof, relates to material science in general, and, more particularly, to sequence variants of Stable Protein 1 (SP1), to uses thereof, for binding of carbon nanotubes, production of composite polymers and polymer materials, such as fabrics, based on SP1-polypeptide-carbon nanotube-complexes, and the use thereof for enhancing conductivity in tire.